Saudi Arabia has suspended the professional licences of two doctors following an investigation into a promotional video that promoted exosome injections as a safe procedure. The Ministry of Health's action signals tighter regulatory scrutiny on unapproved aesthetic treatments, a development that overseas distributors and clinic buyers should monitor for compliance risks and market access implications.
Regulatory action
The Saudi Ministry of Health suspended the licences of two doctors after investigating a promotional video that surfaced on social media. The clip allegedly used professional titles and family connections to gain public trust and promote exosome injections as safe. Authorities completed required regulatory procedures before issuing the suspension.
Official statement on treatment approval
The ministry stressed that all medical treatments and procedures must be approved and licensed for their intended use. It emphasised that approval of any cosmetic product for external use does not permit its injection or promotion with unapproved medical claims. Healthcare practitioners and medical institutions were urged to adhere strictly to authorised indications and regulatory requirements.
Professional ethics reminder
"We call upon everyone to abide by approved uses in accordance with scientific and regulatory standards. The Ministry also stresses the importance of healthcare practitioners adhering to professional ethics and their professional responsibilities," the ministry said in a statement.
Market context
The incident comes amid growing interest in exosome-based treatments, which have gained popularity in some cosmetic and aesthetic medicine circles. The regulatory action signals that Saudi authorities are actively policing unapproved claims and procedures, which could affect the import and distribution of related products.
What buyers should watch
Distributors and clinic buyers supplying aesthetic injectables to the Saudi market should verify that all products have explicit regulatory approval for their intended use. Promotional materials must avoid unapproved medical claims. The case underscores the importance of compliance with local licensing and marketing rules to avoid supply disruptions or legal penalties.
Source: Read the original report | Published: June 18, 2026